Suchergebnisse - "F0P408N6V4"

PubPharm (1.251)

1

Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk

enthalten in: Blood cancer journal | 2024

von Callander, N. | Silbermann, R. | Kaufman, J. | +33

2

Adjusted Indirect Treatment Comparison of Progression-Free Survival with D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data

enthalten in: Advances in therapy | 2024

von Durie, B. | Kumar, S. | Ammann, E. | +5

3

Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma : An open label, phase 2 study

enthalten in: Cancer | 2024

von Gordon, M. | Feng, L. | Strati, P. | +20

4

Use Via Early Access to Ixazomib (UVEA-IXA) Study : Effectiveness and Safety of Ixazomib-based Therapy in Relapsed/Refractory Multiple Myeloma Outside of the Clinical Trial Setting

enthalten in: Clinical lymphoma, myeloma & leukemia | 2024

von Ludwig, H. | Ramasamy, K. | Mateos, M. | +10

5

Daratumumab for patients with myeloma with early or late relapse after initial therapy : subgroup analysis of CASTOR and POLLUX

enthalten in: Blood advances | 2024

von Spencer, A. | Moreau, P. | Mateos, M. | +17

6

MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma : the Nordic Lymphoma Group MCL7 VALERIA trial

enthalten in: Blood advances | 2024

von Jerkeman, M. | Kolstad, A. | Hutchings, M. | +12

7

Hypofractionated radiotherapy combined with lenalidomide improves systemic antitumor activity in mouse solid tumor models

enthalten in: Theranostics | 2024

von Onyshchenko, K. | Luo, R. | Rao, X. | +5

8

Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma

enthalten in: Blood cancer discovery | 2024

von Welsh, S. | Barwick, B. | Meermeier, E. | +30

CommentIn: Blood Cancer Discov. 2024 Jan 8;5(1):5-7. - PMID 38085608

9

CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma

enthalten in: Frontiers in immunology | 2024

von Hontecillas-Prieto, L. | García-Domínguez, D. | Palazón-Carrión, N. | +27

10

Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone : Subanalysis of the randomized phase 3 ATLAS trial

enthalten in: British journal of haematology | 2023

von Kubicki, T. | Dytfeld, D. | Wróbel, T. | +22

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[126]